Stock listing

Xetra:BH3 PTC Therapeutics, Inc. Aktie

German listing (Xetra) of PTC Therapeutics, Inc. · home listing NASDAQ:PTCT

Follow PTC Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:PTCT

$56.42 USD -3.81 (-6.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PTCT

Past year -26.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$56.18 – $58.96 USDNov 20, 2026
Volume
952,599 sharesNov 20, 2026
Market cap
$4.71B USDAt the close on Nov 20, 2026 · price × 83.54M shares outstanding
52-week range
$56.18 – $90.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$69.05M USDMedian day 965,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PTC Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PTCT · Home$56.42 USD-3.81 (-6.3%)952,599$58.80$58.96$56.18$60.23Close on Nov 20, 2026
Dusseldorf:BH3€51.76 EUR-1.76 (-3.3%)—€51.94€52.32€51.76€53.52Close on Nov 20, 2026
Frankfurt:BH3€51.62 EUR-1.60 (-3.0%)—€51.58€51.62€51.58€53.22Close on Nov 20, 2026
Munich:BH3€53.08 EUR-2.96 (-5.3%)—€53.08€53.08€53.08€56.04Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PTCT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$56.42-3.81-6.3%$58.80$58.96$56.18952,599
$60.23-0.13-0.2%$59.99$60.80$59.86640,646
$60.36-0.61-1.0%$60.63$60.97$58.881,077,752
$60.97-2.52-4.0%$63.26$63.95$60.62738,542
$63.49+0.13+0.2%$63.12$63.74$62.51502,867
$63.36-1.55-2.4%$64.56$64.86$63.27538,717
$64.91+0.77+1.2%$64.03$65.04$63.84719,597
$64.14-0.89-1.4%$64.46$65.15$63.52630,008
$65.03-0.41-0.6%$66.91$66.91$64.13843,279
$65.44-0.23-0.4%$65.99$66.67$65.18889,219
$65.67-3.30-4.8%$68.80$69.59$65.451,228,468
$68.97+0.85+1.2%$69.68$70.11$66.871,266,047
$68.12+7.24+11.9%$64.14$68.72$63.162,643,738
$60.88+0.91+1.5%$61.05$62.16$59.161,334,171
$59.97-4.49-7.0%$64.75$65.34$59.652,349,386
$64.46+1.44+2.3%$63.51$65.00$63.511,523,222
$63.02+0.93+1.5%$61.47$63.11$61.00902,770
$62.09+1.02+1.7%$61.07$62.28$59.871,114,121
$61.07+0.48+0.8%$60.84$61.85$60.46708,009
$60.59-2.45-3.9%$62.30$63.49$59.97674,200
$63.04+0.42+0.7%$62.62$63.49$62.24675,400
$62.62-0.30-0.5%$63.14$63.74$62.41944,200
$62.92+1.39+2.3%$62.27$63.24$61.58965,800
$61.53+2.29+3.9%$60.13$61.74$59.35944,000
$59.24-1.75-2.9%$61.08$61.73$58.98789,000
$60.99+1.32+2.2%$61.08$62.31$59.881,051,900
$59.67-0.25-0.4%$59.30$60.69$58.801,519,800
$59.92-3.00-4.8%$62.64$62.75$59.821,051,400
$62.92-1.78-2.8%$64.80$65.03$62.88745,200
$64.70+2.14+3.4%$62.52$64.73$62.201,171,200
$62.56-0.67-1.1%$62.66$62.86$61.651,227,500
$63.23-0.47-0.7%$63.19$64.04$62.841,040,500
$63.70+0.05+0.1%$64.53$65.27$62.921,265,000
$63.65+0.19+0.3%$63.42$64.47$62.601,044,000
$63.46-0.67-1.0%$64.81$65.40$62.80895,600
$64.13-0.65-1.0%$64.70$65.57$63.401,197,800
$64.78-0.18-0.3%$65.16$65.50$64.151,043,300
$64.96-0.99-1.5%$65.51$65.97$64.27900,400
$65.95+3.28+5.2%$62.35$66.26$62.301,913,800
$62.67+0.39+0.6%$62.65$63.44$61.661,203,000
$62.28-0.06-0.1%$62.23$62.76$61.231,754,200
$62.34-3.62-5.5%$65.80$66.15$62.241,101,100
$65.96+0.70+1.1%$66.24$66.58$65.361,307,200
$65.26-0.11-0.2%$65.93$66.21$64.991,086,200
$65.37-2.63-3.9%$68.00$68.01$65.183,865,000
$68.00+0.41+0.6%$68.84$68.84$67.221,115,300
$67.59+1.94+3.0%$65.99$67.90$65.801,397,900
$65.65-0.83-1.2%$66.51$66.54$65.061,034,200
$66.48+0.42+0.6%$67.09$67.99$65.911,018,800
$66.06-1.31-1.9%$67.80$68.48$65.91792,900
$67.37-0.20-0.3%$66.84$67.78$66.471,007,000
$67.57-1.24-1.8%$68.08$68.84$67.501,066,500
$68.81-0.49-0.7%$67.81$70.08$67.481,118,300
$69.30-2.10-2.9%$70.62$71.41$69.26673,500
$71.40-0.39-0.5%$71.76$71.97$70.55654,500
$71.79+1.23+1.7%$71.15$72.68$69.84902,600
$70.56+1.02+1.5%$69.42$70.84$69.05691,000
$69.54-0.55-0.8%$69.98$70.42$68.76841,100
$70.09-1.72-2.4%$71.08$71.49$69.61692,700
$71.81-0.88-1.2%$72.11$72.66$70.91746,300
$72.69-0.78-1.1%$73.18$73.53$71.81533,600
$73.47+2.41+3.4%$71.69$73.47$71.69624,463
$71.06+1.24+1.8%$69.67$71.45$68.02897,681
$69.82-0.70-1.0%$70.54$71.36$69.79674,700
$70.52-3.15-4.3%$73.05$73.56$70.46802,500
Ticker
Xetra:BH3
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All PTC Therapeutics, Inc. news

PTC Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 217 in all · newest Nov 3, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Oct 29, 2026
Decks
33 decks · latest Oct 29, 2026

Where PTC Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PTCT · Home listingNASDAQUnited StatesUSD
gettex:BH3gettexGermanyEUR
LS Exchange:A1W0MWLS ExchangeGermanyEUR
Lang & Schwarz:A1W0MWLang & SchwarzGermanyEUR
BOATS:PTCTBOATSUnited StatesUSD
BX Swiss:P91BX SwissSwitzerlandCHF
Dusseldorf:BH3DusseldorfGermanyEUR
Frankfurt:BH3FrankfurtGermanyEUR
Hamburg:BH3HamburgGermanyEUR
Munich:BH3MunichGermanyEUR
Stuttgart:BH3StuttgartGermanyEUR
Tradegate:BH3TradegateGermanyEUR
Hanover:BH3HanoverGermanyEUR
Xetra:BH3 · This pageXetraGermanyEUR

Valuation

EV/sales 2.7× against a median of 7.0×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.12B USD
P/E
Loss
EV/sales
2.7×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
Not reported
Operating margin
12.8%
Net margin
−9.2%
Debt to equity
Negative equity
Beta vs S&P 500
0.88

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.05BUS$4.77B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Edgewise Therapeutics, Inc. · NASDAQ:EWTXUS$4.37BUS$2.63B4.3×n/an/a2.7×n/a0.0×1.12
Median of the othersUS$4.70BUS$4.19B16.9×7.0×25.0×6.4×−15.2%0.0×1.12

Forecasts

9 strong buy · 4 buy · 2 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
100.47 USD · Analysts' mean
EPS, year to Dec 2026
0.94 · 2 analysts
Revenue, year to Dec 2026
1.32B · 14 analysts

Team and board

Officers

OfficerRole
Matthew B. KleinChief Executive Officer
Pierre GravierChief Financial Officer
Mark E. BouldingExecutive Vice President and Chief Legal Officer
Christine UtterSenior Vice President, Chief Accounting Officer and Head of People Services
Linda Montella-CarterSenior Vice President and Chief Information Officer
Mary Frances HarmonSenior Vice President, Corporate and Patient Relations
Patrice ThorntonSenior Vice President, Human Resources
Eric PauwelsChief Business Officer
John BairdChief of Staff to the CEO
Lee GoldenChief Medical Officer
Neil AlmsteadChief Technical Operations Officer

Board

DirectorRole
Glenn D. SteeleChairman, GSteele Health Solutions
Michael SchmertzlerChairman
Jessica ChutterDirector

Events

Calls

CallWhenStatus
PTC Therapeutics (NASDAQ:PTCT) Q3 2026 Earnings CallThu, Oct 29, 2026 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2026 Earnings CallThu, Jul 30, 2026 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q1 2026 Earnings CallThu, May 07, 2026 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q4 2025 Earnings CallThu, Feb 19, 2026 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q3 2025 Earnings CallTue, Nov 04, 2025 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q4 2024 Earnings CallThu, Feb 27, 2025 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
All 22 calls
CallWhenStatus
PTC Therapeutics (NASDAQ:PTCT) Q1 2024 Earnings CallThu, Apr 25, 2024 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q4 2023 Earnings CallThu, Feb 29, 2024 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q3 2023 Earnings CallThu, Oct 26, 2023 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2023 Earnings CallThu, Aug 03, 2023 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q1 2023 Earnings CallThu, Apr 27, 2023 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q4 2022 Earnings CallTue, Feb 21, 2023 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q3 2022 Earnings CallThu, Oct 27, 2022 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q1 2022 Earnings CallTue, May 03, 2022 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q4 2021 Earnings CallTue, Feb 22, 2022 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q3 2021 Earnings CallThu, Oct 28, 2021 · 4:30 PM ETReplay
PTC Therapeutics (NASDAQ:PTCT) Q2 2021 Earnings CallThu, Jul 29, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · After close−7.0%
Q2 2026Jul 30, 2026 · After close−9.9%
Q1 2026May 7, 2026 · After close+14.3%
Q4 2025Feb 19, 2026 · After close+1.1%
Q3 2025Nov 4, 2025 · After close+6.0%
Q2 2025Aug 7, 2025 · After close−9.9%
Q1 2025May 6, 2025 · After close+12.6%
Q4 2024Feb 26, 2025 · After close−0.8%
Q3 2024Nov 7, 2024 · After close+3.1%
Q2 2024Aug 8, 2024 · After close−3.6%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 25, 2024 · After close+12.1%
Q4 2023Feb 29, 2024 · After close+13.3%
Q3 2023Oct 26, 2023 · After close−22.7%
Q2 2023Aug 3, 2023 · After close−4.0%
Q1 2023Apr 27, 2023 · After close+4.8%
Q4 2022Feb 21, 2023 · After close−1.1%
Q3 2022Oct 27, 2022 · After close−13.7%
Q2 2022Aug 4, 2022 · After close+8.7%
Q1 2022May 3, 2022 · After close+2.7%
Q4 2021Feb 22, 2022 · After close−7.3%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update31 slidesOct 29, 2026
Investor Presentation (July 2026)Investor deck28 slidesJuly 2026
Technical Presentation (April 2026)Technical18 slidesApr 28, 2026
J.P. Morgan 2026 Healthcare ConferenceConference25 slidesJan 12, 2026
Investor Day (December 2025)Investor day113 slidesDec 2, 2025
Technical Presentation (May 2025)Technical22 slidesMay 5, 2025
J.P. Morgan Healthcare Conference 2025Conference31 slidesJan 13, 2025
Technical Presentation (June 2024)Technical25 slidesJun 20, 2024
J.P. Morgan Healthcare Conference 2024Conference30 slidesJan 8, 2024
Investor Day (July 2023)Investor day58 slidesJul 19, 2023
All 33 decks
DeckKindSlidesDate
Investor Day (July 2023)Investor day59 slidesJul 19, 2023
Technical Presentation (June 2023)Technical14 slidesJun 21, 2023
Technical Presentation (May 2023)Technical14 slidesMay 23, 2023
Technical Presentation (May 2023)Technical19 slidesMay 17, 2023
Technical Presentation (May 2023)Technical21 slidesMay 2023
JP Morgan Healthcare Conference 2023Conference34 slidesJan 9, 2023
Technical Presentation (2023)Technical15 slides2023
Investor Presentation (September 2022)Investor deck42 slidesSep 7, 2022
Technical Presentation (June 2022)Technical36 slidesJun 21, 2022
William Blair Growth Stock Conference 2022Conference31 slidesJun 9, 2022
2022 J.P. Morgan Healthcare ConferenceConference42 slidesJan 10, 2022
Investor Presentation (November 2021)Investor deck53 slidesNov 30, 2021
Technical Presentation (September 2021)Technical33 slidesSep 23, 2021
Technical Presentation (April 2021)Technical70 slidesApr 15, 2021
Corporate Update (February 2021)Corporate update16 slidesFeb 4, 2021
2021 J.P. Morgan Healthcare ConferenceConference51 slidesJan 11, 2021
2020 J.P. Morgan Healthcare ConferenceConference37 slidesJan 17, 2020
2019 JP Morgan Healthcare ConferenceConference39 slidesJan 7, 2019
Q2 2018 Earnings PresentationEarnings10 slidesAug 7, 2018
Technical Presentation (January 2018)Technical18 slidesJan 29, 2018
Conference Presentation (January 2018)Conference28 slidesJan 10, 2018
PPMD 2017 Connect ConferenceConference23 slidesJun 30, 2017
35th Annual JP Morgan Healthcare Conference (January 2017)Conference29 slidesJan 9, 2017

Open Decks

Financings

RaiseDate
0% Convertible Senior Notes due 2031
Update: US$500M
Use of proceeds: About $328.8 million to repurchase 2026 convertible notes; rest for general corporate purposes, including further repurchases or repayment of 2026 notes
Jun 16, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.73B806.8M937.8M698.8M538.6M380.8M307.0M264.7M194.4M82.7M
Cost of revenue12.1M12.7M4.58M0
Gross profit294.8M252.1M189.8M82.7M
Research and development455.2M534.5M666.6M651.5M540.7M477.6M257.5M172.0M117.5M117.6M
Selling, general and administrative347.1M300.9M332.5M326.0M285.8M245.2M202.5M153.5M121.3M97.1M
Operating income866.9M-302.6M-439.5M-447.4M-374.4M-431.8M-241.2M-115.7M-64.3M-132.1M
Depreciation and amortization38.8M75.7M236.6M128.8M64.1M43.5M32.2M26.1M17.7M3.29M
EBITDA905.8M-226.9M-202.9M-318.6M-310.3M-388.3M-209.0M-89.6M-46.6M-128.8M
Income before tax696.6M-363.1M-696.1M-587.5M-518.3M-402.9M-239.9M-128.1M-77.7M-141.5M
Income tax14.0M176.0K-69.5M-28.5M5.56M35.2M11.7M-29.0K1.33M569.0K
Net income682.6M-363.3M-626.6M-559.0M-523.9M-438.2M-251.6M-128.1M-79.0M-142.1M
Earnings per share, basic8.58-4.73-8.37-7.79-7.43-6.64-4.27-2.75-2.02-4.17
Earnings per share, diluted7.78-4.73-8.37-7.79-7.43-6.64-4.27-2.75-2.02-4.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents984.6M779.7M594.0M279.8M189.7M208.8M288.0M169.5M111.8M58.3M
Short-term investments960.7M360.0M282.7M130.9M583.7M894.8M398.5M58.1M79.5M173.3M
Receivables181.6M158.6M160.8M155.6M110.5M69.9M55.5M67.9M40.4M24.9M
Inventory79.6M23.2M30.6M21.8M15.9M18.7M19.3M16.1M10.8M0
Current assets2.27B1.37B1.22B693.8M954.4M1.23B779.3M320.9M249.1M261.3M
Property, plant and equipment55.4M61.0M87.1M72.6M52.6M33.8M21.5M12.7M8.38M7.43M
Goodwill82.3M82.3M82.3M82.3M82.3M82.3M82.3M82.3M0
Total assets2.90B1.71B1.90B1.71B1.94B2.21B1.62B1.12B391.7M269.3M
Accounts payable45.5M17.3M6.04M27.3M23.0M18.7M10.3M6.00M15.3M6.30M
Current liabilities968.4M581.0M603.1M406.2M509.3M277.3M235.9M166.8M82.0M49.6M
Long-term debt285.4M284.2M571.7M281.9M309.1M293.9M141.3M145.0M98.2M
Total debt286.6M285.4M284.2M571.7M431.4M309.1M313.9M153.0M145.0M98.2M
Total liabilities3.10B2.80B2.71B2.05B1.94B1.73B1.03B768.5M235.2M149.8M
Shareholders' equity-205.3M-1.10B-818.6M-347.1M1.44M482.0M594.3M350.7M156.4M119.6M
Shares outstanding81.5M77.7M75.7M73.1M70.8M69.7M61.9M50.6M41.6M34.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations711.2M-107.7M-158.4M-356.7M-251.3M-194.1M-98.6M-27.6M-10.1M-103.6M
Capital spending-8.86M-6.50M-28.4M-32.0M-28.2M-17.8M-13.8M-7.10M-3.10M-1.78M
Free cash flow702.3M-114.2M-186.9M-388.7M-279.5M-211.9M-112.4M-34.7M-13.2M-105.3M
Cash from investing-862.0M44.2M-176.7M290.2M219.2M-561.5M-387.2M-42.6M13.1M104.5M
Cash from financing331.1M255.9M646.4M168.0M20.9M668.7M613.2M131.6M44.2M968.0K
Change in cash203.0M185.0M314.4M98.7M-19.1M-79.2M126.0M57.7M53.5M299.0K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 3, 2026Current reportSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 9, 2026Insider tradeSEC
144 · Notice of proposed saleOct 9, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 7, 2026Other filingsSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
8-K · Current reportSep 21, 2026Current reportSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
8-K · Current reportAug 28, 2026Material contractSEC
144/A · Notice of proposed sale, amendedAug 25, 2026Other filingsSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
8-K · Current reportAug 13, 2026Current reportSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
144 · Notice of proposed saleJul 14, 2026Other filingsSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 18, 2026Material contractSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
8-K · Current reportJun 16, 2026Current reportSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
8-K · Current reportJun 9, 2026Management or board changeSEC
8-K · Current reportJun 5, 2026Meeting outcomeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
8-K · Current reportApr 28, 2026Current reportSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 20, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 20, 2026Meeting noticeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 26, 2026Insider tradeSEC
8-K · Current reportMar 25, 2026Management or board changeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
144 · Notice of proposed saleMar 10, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
10-K · Annual reportFeb 19, 2026Annual reportSEC
8-K · Current reportFeb 19, 2026ResultsSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 12, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleDec 30, 2025Other filingsSEC
8-K · Current reportDec 29, 2025Material contractSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 18, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 4, 2025Big-stake noticeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from PTC Therapeutics, Inc.’s releases · as of Oct 27, 2026

Common shares
83,544,284
Fully diluted
83,544,284

Fully diluted

LineSharesAs of
Common shares83,544,284Oct 27, 2026

Share count over time

CountShares
Oct 27, 202683,544,284

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock14.4MUS$933MSep 30, 2026
Vanguard9.31MUS$603MSep 30, 2026
Janus Henderson6.87MUS$445MSep 30, 2026
State Street5.51MUS$357MSep 30, 2026
Wellington5.28MUS$342MSep 30, 2026
Westfield Capital Management Co LP2.7MUS$175MSep 30, 2026
Geode Capital2.15MUS$139MSep 30, 2026
UBS2.02MUS$131MSep 30, 2026
Hood River Capital Management LLC1.76MUS$114MSep 30, 2026
William Blair Investment Management, LLC1.69MUS$110MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Goldman Sachs1.62MUS$105MSep 30, 2026
Rtw Investments, LP1.62MUS$105MSep 30, 2026
Tang Capital Management LLC1.5MUS$97.2MSep 30, 2026
Bank of America1.42MUS$92.1MSep 30, 2026
Point72 Asset Management, L.P.1.41MUS$91.3MSep 30, 2026
Armistice Capital, LLC1.3MUS$84.1MSep 30, 2026
Driehaus Capital Management LLC1.24MUS$80.1MSep 30, 2026
Fidelity1.22MUS$78.9MSep 30, 2026
Fuller & Thaler Asset Management, Inc.1.21MUS$78.2MSep 30, 2026
Franklin Templeton1.05MUS$72.7MSep 30, 2026
BNP Paribas1.02MUS$65.9MSep 30, 2026
Schwab908KUS$58.8MSep 30, 2026
Palo Alto Investors LP875KUS$56.7MSep 30, 2026
Northern Trust867KUS$56.2MSep 30, 2026
Boston Partners863KUS$55.9MSep 30, 2026
Pictet Asset Management Holding SA838KUS$54.3MSep 30, 2026
T. Rowe Price834KUS$54MSep 30, 2026
Renaissance Technologies787KUS$51MSep 30, 2026
Jupiter Asset Management LTD770KUS$49.9MSep 30, 2026
Morgan Stanley761KUS$49.3MSep 30, 2026
Parkman Healthcare Partners LLC700KUS$45.4MSep 30, 2026
Qube Research & Technologies Ltd677KUS$43.9MSep 30, 2026
JPMorgan654KUS$42.7MSep 30, 2026
Loomis Sayles & Co L P640KUS$41.4MSep 30, 2026
D. E. Shaw & Co., Inc.619KUS$40.1MSep 30, 2026
Susquehanna605KUS$39.2MSep 30, 2026
Federated Hermes, Inc.576KUS$37.3MSep 30, 2026
American Century566KUS$36.7MSep 30, 2026
Arrowstreet Capital, Limited Partnership519KUS$33.6MSep 30, 2026
BNY512KUS$33.2MSep 30, 2026
Voya Investment Management LLC503KUS$32.6MSep 30, 2026
Allianz503KUS$32.6MSep 30, 2026
Dimensional492KUS$31.9MSep 30, 2026
Russell Investments Group, Ltd.464KUS$30MSep 30, 2026
Public Sector Pension Investment Board452KUS$27.1MSep 30, 2026
Manufacturers Life Insurance Company, The442KUS$28.6MSep 30, 2026
Lord, Abbett & Co. LLC428KUS$27.7MSep 30, 2026
Citadel427KUS$27.7MSep 30, 2026
Invesco424KUS$27.5MSep 30, 2026
AQR Capital Management LLC414KUS$26.8MSep 30, 2026

This page holds 50 of 351 holders. Open Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Small-Cap ETF5MUS$408MJun 30, 2026
Vanguard Total Stock Market Index Fund2.64MUS$215MJun 30, 2026
Vanguard Health Care Fund2.31MUS$157MJul 31, 2026
iShares Russell 2000 ETF2.13MUS$174MJun 30, 2026
Vanguard Small-Cap Index Fund1.9MUS$155MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.36MUS$111MJun 30, 2026
Vanguard Small-Cap Growth Index Fund1.1MUS$89.5MJun 30, 2026
Janus Henderson Global Life Sciences Fund996KUS$81.2MJun 30, 2026
Vanguard Extended Market Index Fund951KUS$77.6MJun 30, 2026
Fidelity Small Cap Index Fund905KUS$61.6MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Hood River Small-Cap Growth Fund832KUS$67.9MJun 30, 2026
Fullerthaler Behavioral Small-Cap Growth780KUS$63.6MJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF762KUS$62.2MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF745KUS$60.8MJun 30, 2026
iShares Russell 2000 Growth ETF653KUS$53.3MJun 30, 2026
Invesco S&P SmallCap Momentum ETF639KUS$43.5MJul 31, 2026
Harbor Small Cap Growth Fund569KUS$38.7MJul 31, 2026
iShares Biotechnology ETF568KUS$46.3MJun 30, 2026
Janus Henderson Triton Fund541KUS$44.1MJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund511KUS$41.7MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund475KUS$38.8MJun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF471KUS$38.4MJun 30, 2026
Lord Abbett Developing Growth Fund Inc427KUS$29MJul 31, 2026
Fidelity Extended Market Index Fund413KUS$30.5MMay 31, 2026
Vanguard Russell 2000 Index Fund405KUS$29.9MMay 31, 2026
Schwab U.S. Small-Cap ETF386KUS$28.5MMay 31, 2026
Small Cap Growth Fund380KUS$25.8MJul 31, 2026
Janus Henderson Venture Fund366KUS$29.8MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.352KUS$28.7MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund332KUS$24.5MMay 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund303KUS$24.8MJun 30, 2026
Franklin Biotechnology Discovery Fund280KUS$19MJul 31, 2026
Vanguard S&P Small-Cap 600 Index Fund278KUS$20.5MMay 31, 2026
Column Small Cap Select Fund269KUS$19.8MMay 31, 2026
Federated Hermes MDT Small Cap Core Fund228KUS$15.5MJul 31, 2026
Dimensional U.S. Small Cap ETF224KUS$15.3MJul 31, 2026
Vanguard Health Care Index Fund217KUS$16MMay 31, 2026
Franklin Small Cap Growth Fund203KUS$13.8MJul 31, 2026
Schwab Small-Cap Index Fund201KUS$13.7MJul 31, 2026
Loomis Sayles Small Cap Growth Fund194KUS$15.9MJun 30, 2026
Driehaus Small Cap Growth Fund189KUS$15.5MJun 30, 2026
William Blair Small-Mid Cap Growth Fund184KUS$15MJun 30, 2026
William Blair Small Cap Growth Fund181KUS$14.7MJun 30, 2026
JNL Multi-Manager Small Cap Growth Fund168KUS$13.7MJun 30, 2026
Nuveen Quant Small Cap Equity Fund167KUS$11.3MJul 31, 2026
Voya Small Cap Growth Fund165KUS$12.2MMay 31, 2026
Select Biotechnology Portfolio160KUS$11.8MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF155KUS$12.6MJun 30, 2026
Master Small Cap Index Series153KUS$12.5MJun 30, 2026
Fidelity Total Market Index Fund152KUS$11.2MMay 31, 2026

This page holds 50 of 413 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale1,315USD 61.39US$80,728Nov 16, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale1,288USD 62.22US$80,139Nov 16, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale209USD 62.90US$13,146Nov 16, 2026
Schmertzler Michael
Director
Sale2,118USD 59.52US$126KOct 14, 2026
Schmertzler Michael
Director
Sale382USD 60.14US$22,973Oct 14, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale192USD 64.26US$12,338Oct 9, 2026
Schmertzler Michael
Director
Sale2,447USD 63.38US$155KOct 7, 2026
Schmertzler Michael
Director
Sale53USD 63.95US$3,389Oct 7, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale435USD 64.16US$27,910Oct 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale1,638USD 64.03US$105KOct 5, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Steele Glenn Jr Md Phd
Director
Sale12,000USD 65.16US$782KSep 30, 2026
Schmertzler Michael
Director
Sale9,624USD 67.83US$653KSep 17, 2026
Schmertzler Michael
Director
Sale376USD 68.45US$25,737Sep 17, 2026
Schmertzler Michael
Director
Sale2,994USD 66.58US$199KSep 16, 2026
Schmertzler Michael
Director
Sale7,006USD 67.35US$472KSep 16, 2026
Schmertzler Michael
Director
Sale10,000USD 67.34US$673KSep 10, 2026
Schmertzler Michael
Director
Sale9,428USD 67.79US$639KSep 9, 2026
Schmertzler Michael
Director
Sale572USD 68.67US$39,279Sep 9, 2026
Schmertzler Michael
Director
Sale11,890USD 71.55US$851KAug 27, 2026
Schmertzler Michael
Director
Sale610USD 72.22US$44,054Aug 27, 2026
Schmertzler Michael
Director
Sale6,874USD 72.74US$500KAug 26, 2026
Schmertzler Michael
Director
Sale5,626USD 73.18US$412KAug 26, 2026
Schmertzler Michael
Director
Sale9,419USD 70.78US$667KAug 20, 2026
Schmertzler Michael
Director
Sale2,390USD 71.88US$172KAug 20, 2026
Schmertzler Michael
Director
Sale691USD 72.92US$50,388Aug 20, 2026
Schmertzler Michael
Director
Sale5,335USD 72.86US$389KAug 19, 2026
Schmertzler Michael
Director
Sale7,165USD 73.67US$528KAug 19, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale1,844USD 72.39US$133KAug 17, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale969USD 72.90US$70,640Aug 17, 2026
Klein Matthew B.
Director, Officer: CHIEF EXECUTIVE OFFICER
Sale10,292USD 68.57US$706KAug 4, 2026
Gravier Pierre
Officer: CHIEF FINANCIAL OFFICER
Sale3,494USD 80.35US$281KJul 14, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale2,464USD 90.25US$222KJul 9, 2026
Smith Mary L.
Director
Sale10,000USD 90.00US$900KJul 9, 2026
Smith Mary L.
Director
Sale5,834USD 90.00US$525KJul 9, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale3,956USD 87.17US$345KJul 7, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale11,369USD 89.03US$1.01MJul 7, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale9,288USD 89.44US$831KJul 7, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale426USD 85.28US$36,329Jul 6, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale385USD 86.34US$33,241Jul 6, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale8,786USD 85.35US$750KJul 6, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale10,090USD 86.32US$871KJul 6, 2026
Almstead Neil Gregory
Officer: CHIEF TECHNICAL OPS OFFICER
Sale2,474USD 87.03US$215KJul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale313USD 83.10US$26,010Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale833USD 84.41US$70,314Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale519USD 85.84US$44,551Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale601USD 86.38US$51,914Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale387USD 83.10US$32,160Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale1,036USD 84.41US$87,449Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale645USD 85.84US$55,367Jul 6, 2026
Boulding Mark Elliott
Officer: EXEC. VP AND CLO
Sale745USD 86.38US$64,353Jul 6, 2026

This page holds 50 of 85 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.14.80%11.9MNov 30, 2025Schedule 13G
Janus Henderson Group PLC8.70%7.19MMar 31, 2026Schedule 13G
Armistice Capital, LLC6.86%5.43MMar 31, 2025Schedule 13G
State Street Corp6.60%5.51MSep 30, 2026Schedule 13G
Wellington Management Group LLP6.30%5.29MSep 30, 2026Schedule 13G
Vanguard Portfolio Management LLC5.88%4.87MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC5.17%4.28MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adam Koppel
Other companies: Kailera Therapeutics, Inc. (Partner, Bain Capital Life Sciences · Since at least Apr 16, 2026); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Foghorn Therapeutics Inc. (Director · Oct 22, 2020 – Dec 29, 2024 · Past); BCLS Acquisition Corp (Director · Oct 21, 2020 – Oct 26, 2020 · Past); Replimune Group, Inc. (Director · Jul 24, 2018 – Jul 24, 2018 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Dicerna Pharmaceuticals Inc (Director · Apr 11, 2017 – Dec 28, 2021 · Past); Trevena, Inc. (Director · Sep 17, 2014 – May 16, 2018 · Past); Biogen Inc. (EVP, Strategy and Bus. Dev. · May 15, 2014 – Jun 6, 2016 · Past)
Director · Jun 19, 2013 – Jan 3, 2017 · Past
Ronald C Renaud Jr
Other companies: Kailera Therapeutics, Inc. (CEO & President, Director · Since at least Apr 16, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Cerevel Therapeutics Holdings Inc (President & CEO, Director · Jun 12, 2023 – Aug 1, 2024 · Past); ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 9, 2022 · Past); Atara Biotherapeutics, Inc. (Director · Apr 29, 2020 – Jun 23, 2022 · Past); Translate Bio Inc (Chief Executive Officer, Director · Jun 27, 2018 – Sep 14, 2021 · Past); Chimerix Inc (Director · Dec 17, 2014 – Jun 20, 2019 · Past); Akebia Therapeutics, Inc. (Director · Sep 12, 2014 – Jun 14, 2018 · Past); Idenix Pharmaceuticals Inc (President & CEO, Director · Jun 28, 2007 – Aug 5, 2014 · Past); Keryx Biopharmaceuticals Inc (Chief Financial Officer · Feb 14, 2006 – Feb 14, 2007 · Past)
Director · Jun 10, 2014 – Jan 3, 2017 · Past
Jerome Zeldis
Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); Soligenix, Inc. (Board Director · Since at least Jun 22, 2011); NexImmune, Inc. (Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Sorrento Therapeutics, Inc. (See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past)
Director · Since at least Jun 19, 2013
David P. Southwell
Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Feb 17, 2015); TScan Therapeutics, Inc. (Chief Executive Officer, Director · Jul 15, 2021 – Feb 2, 2023 · Past); Spero Therapeutics, Inc. (Director · Feb 1, 2018 – Jun 5, 2018 · Past); Human Genome Sciences Inc (Chief Financial Officer · Jul 23, 2008 – Jul 30, 2012 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Chief Financial Officer · Dec 31, 2005 – Sep 10, 2007 · Past)
Director · Since at least Jun 19, 2013
Dawn Svoronos
Other companies: Adverum Biotechnologies Inc (Director · Since at least Dec 9, 2020); Xenon Pharmaceuticals Inc. (Director · Since at least Sep 27, 2016); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Global Blood Therapeutics Inc (Director · Dec 19, 2018 – Oct 5, 2022 · Past); Endocyte Inc (Director · May 3, 2018 – Dec 21, 2018 · Past); Medivation Inc (Director · Apr 22, 2013 – Sep 28, 2016 · Past)
Director · Jun 10, 2016 – Jun 9, 2022 · Past
Axel Bolte
Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 8, 2018 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – Jul 11, 2023 · Past)
Director · Jun 19, 2013 – Jun 25, 2013 · Past
Emma Reeve
Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Sep 8, 2021); Editas Medicine, Inc. (Director · Sep 3, 2021 – May 30, 2024 · Past); Constellation Pharmaceuticals Inc (Chief Financial Officer · Jul 18, 2018 – Jul 15, 2021 · Past); PAREXEL International Corp (Corp. VP & Interim CFO · Jul 16, 2016 – Dec 7, 2016 · Past)
Director · Since at least Dec 14, 2018
Richard Aldrich
Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 3, 2018 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Dec 7, 2018 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past)
Director · Mar 7, 2013 – Jun 8, 2015 · Past
Alethia Young
Other companies: Pacira BioSciences, Inc. (Independent Director · Since at least Oct 6, 2023); Bicycle Therapeutics PLC (Chief Financial Officer · Since at least Jul 17, 2023); LENZ Therapeutics, Inc. (Chief Financial Officer · Apr 1, 2022 – Feb 21, 2023 · Past)
Director · Since at least Jun 8, 2022
Marcio Souza
Other companies: Praxis Precision Medicines, Inc. (President & Chief Executive Officer · Since at least Oct 15, 2020); Spyre Therapeutics, Inc. (Director · Jun 18, 2021 – Aug 25, 2022 · Past); ClearPoint Neuro Inc. (Director · May 17, 2019 – May 17, 2019 · Past)
Chief Operating Officer · May 31, 2017 – Feb 10, 2020 · Past
All 36 people
PersonSeat
Stephanie Okey
Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jul 15, 2019); Catalent Inc (Director · Aug 28, 2023 – Dec 18, 2024 · Past); Albireo Pharma Inc (Director · Jun 8, 2018 – Mar 2, 2023 · Past)
Director · Since at least Dec 14, 2018
Lee Golden
Other companies: Cadrenal Therapeutics, Inc. (Board Member · Since at least Nov 24, 2025); MetaVia Inc. (Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past)
EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023
Tuyen Ong
Other companies: Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Nightstar Therapeutics PLC (Chief Development Officer · Jan 1, 2019 – Jun 7, 2019 · Past)
Chief Medical Officer · Apr 22, 2016 – Jan 3, 2017 · Past
Emily Hill
Other companies: Replimune Group, Inc. (Chief Financial Officer · Since at least Sep 18, 2023)
CHIEF FINANCIAL OFFICER · May 31, 2019 – Mar 27, 2023 · Past
Eric Pauwels
Other companies: NPS Pharmaceuticals Inc (President, NPS Pharma Int'l · Oct 17, 2011 – Feb 21, 2015 · Past)
Chief Business Officer · Since at least Apr 16, 2020
Jessica Chutter
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Apr 23, 2026)
Director · Since at least Mar 24, 2026
Matthew B. Klein
Other companies: ClearPoint Neuro Inc. (Director · Since at least Apr 16, 2020)
Chief Executive Officer · Since at least Apr 16, 2020
Michael L Kranda
Other companies: Anesiva Inc (President and CEO, Director · Jun 16, 2008 – Dec 3, 2008 · Past)
Director · Jun 19, 2013 – Mar 16, 2015 · Past
Michael Schmertzler
Other companies: Hamilton Lane Incorporated (Independent Director · Since Jul 22, 2026)
Director · Since at least Jan 29, 2013
Pierre Gravier
Other companies: Filana Therapeutics, Inc. (Independent Director · Since at least Dec 6, 2023)
Chief Financial Officer · Since at least Jul 13, 2023
Shane William Charles Kovacs
Other companies: Olema Pharmaceuticals, Inc. (CH. OPERATING & FINANCIAL OFF. · Since at least Jun 15, 2020)
Chief Financial Officer · Sep 26, 2016 – May 9, 2017 · Past
Stuart Walter Peltz
Other companies: Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past)
CHIEF EXECUTIVE OFFICER, Director · Jun 19, 2013 – Jan 31, 2023 · Past
Allan Steven JacobsonDirector · Since at least Jun 19, 2013
Christine UtterSenior Vice President, Chief Accounting Officer and Head of People Services · Since at least Jun 2, 2017
Glenn D. SteeleChairman, GSteele Health Solutions · Since at least Oct 2, 2026
Glenn Md Phd Steele JrDirector · Since at least Jan 5, 2023
Hege Elisabeth Sollie-ZetlmayerDirector · Since at least Jul 28, 2026
Jay Allan BarthVP, Clinical Development · Jun 19, 2013 – Jun 19, 2013 · Past
John BairdChief of Staff to the CEO · Since at least Nov 5, 2026
Linda Montella-CarterSenior Vice President and Chief Information Officer · Since at least Nov 5, 2026
Mark E. BouldingExecutive Vice President and Chief Legal Officer · Since at least Jan 3, 2018
Mary Frances HarmonSenior Vice President, Corporate and Patient Relations · Since at least Nov 5, 2026
Mary L SmithDirector · Since at least Jun 8, 2021
Neil AlmsteadChief Technical Operations Officer · Since at least Jan 3, 2018
Patrice ThorntonSenior Vice President, Human Resources · Since at least Nov 5, 2026
William F Bell JrDirector · Feb 15, 2024 – Feb 15, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about PTC Therapeutics, Inc.